Abstract:Abstract 2384 Introduction: Allogeneic haematopoietic stem cell transplantation (HSCT) has been used to treat malignant hematological diseases. For patients who do not have a matched sibling donor or a matched unrelated donor (MUD) for transplantation, an eligible HLA-haploidentical donor can be identified rapidly in nearly all cases. However, HLA-haploidentical BMT has been associated with significant risks of complication, such as graft rejection and severe GVHD and infection. Materials and Methods: Thirty eight consecutive patients with malignant hematological diseases received HLA-haploidentical stem cell transplant from April 2008 to June 2010. Eligible patients were 9– 48 years of age with acute myeloid leukemia (n=10),acute lymphocytic leukemia (n=17), myelodysplastic syndrome(n=5), chronic myeloid leukemia (n=4), non Hodgkin lymphoma (n=2). Transplantation conditioning consisted of Ara-C (4 g/m2/d, i.v.) on day -10 and -9, Bu (9.6mg/kg i.v. in 12 doses) on day -8, -7 and -6, Cy (1.8 g/m2/d, i.v.) on day -5 and -4, Me-CCNU (250 mg/kg, i.v.) on day -3, and ATG (2.5 mg/kg/d i.v.) on day -5 to -2. The prophylaxis of aGVHD consisted of cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate. Donors were primed with rhG-CSF (7.5 mg/kg per day) injected subcutaneous (s.c.). Bone marrow cells and peripheral blood stem cells(PBSC) were harvested in nineteen donors, and only PBSC were harvested in the other 19 donors. Results: Primary engraftment was achieved in all patients. All the patients achieved complete donor chimerism in the peripheral blood before day +28. Seven patients (18.4%) had grade I aGVHD, ten (26.3%) had grade II aGVHD, four(10.5%) had grade III aGVHD and four (10.5%) had grade IV aGVHD. II-IV aGVHD occurred in nine patients treated with bone marrow cells and PBSCs, the same number patients suffered from II-IV aGVHD treated with only PBSCs. Transplant related mortality within 100 days after transplantation was 15.8%. At a median follow-up of 10 months (range 2–28months), the overall survival was 68.4%. Conclusion: Haploidentical stem cell transplantation is relatively safe and efficient for the patients who have no HLA matched donors.The results require to confirm and show that G-BM combined with PBSC or G-PBSC from haploidentical family donors have equal effect. Disclosures: No relevant conflicts of interest to declare.

Clinical Treatment of Malignant Lymphoma by Autologous Hematopoietic Stem Cell Transplantation in 40 Patients

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

[Treatment of Malignant Lymphoma by Autologous Hematopoietic Stem Cell Transplantation Combined with High Dose Radiotherapy and Chemotherapy].

Treatment of malignant lymphoma by autologous hematopoietic stem cell transplantation in 15 patients

[Long Term Curative Effects and Prognostic Analysis of Stem Cell Transplantation for Treating Patients with Peripheral T Cell Lymphoma].

[Clinical analysis of 81 cases of malignant lymphoma treated with autologous hematopoietic stem cell transplantation].

Clinical Observation and Long-time Follow-up of Patients with Malignant Lymphoma Treated with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

High-dose chemotherapy following autologous hematopoietic stem cell transplantation for lymphoma:a clinical study

The effects of autologous hemetopoietic stem cell transplantation following high dose chemotherapy for lymphoma

The effects of autologous hemetopoietic stem cell transplantation( Auto-HSCT) for malignant lymphoma

Clinical analysis of double autologous hematopoietic stem cell transplantation for malignant lymphoma

Analysis of autologous hemopoietic stem cell transplantation for 61 patients with hematological malignancies

Effect of hematopoietic stem cell transplantation in malignant hematologic disease of lymphatic system]

Long Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Aggressive T-Cell Non-Hodgkin’s Lymphoma

Efficacy of Hematopoietic Stem Cell Transplantation in the Treatment of 110 Cases Hematologic Malignancies

Clinical Analysis of Non-Hodgkin's Lymphoma Treated by High Does MTX,autologous Peripheral Stem Cell Transplantation and Biotherapy for 43 Cases

Advanced and Recurrent Malignant Lymphoma Were Treated by BEAC Regimen Supported with Autologous Hemotopoietic Stem Cells Transplantation

High-dose therapy combined with autologous peripheral blood stem cell transplantation in patients with peripheral T-cell lymphoma: a retrospective study

A Clinical Study of the Hematopoietic Stem Cell Transplantation in 112 Patients with Leukemia and Other Malignant Diseases

Clinical Observation of Patients with Hematologic Malignancies Treated with Hematopoietic Stem Cell Transplantation.

[Clinical Efficacy of Autologous Hematopoietic Stem Cell Transplantation Using Tumor-ablative Conditioning Regimen for Patients with Refractory/Relapsed Non-Hodgkin's Lymphoma].